[A20-20] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2020
Commission awarded on 25.02.2020 by the Federal Joint Committee (G-BA).
Patients with metastatic hormone-sensitive prostate cancer
For patients in good general condition: hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-36||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-09||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-62||Apalutamide (prostate cancer) - Addendum to Commission A20-20||Commission completed|